FLX475 in Combination With Ipilimumab in Advanced Melanoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of
FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated
with an anti-PD-1 or anti-PD-L1 agent.
The study will be conducted starting with a safety run-in portion in which 6 eligible
subjects will be enrolled and treated for at least one 3-week cycle to determine if the
safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately
20-subject study.